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BACKGROUND: The future risk of myocardial infarction is commonly 
assessed using cardiovascular risk scores, coronary artery calcium score, or 
coronary artery stenosis severity. We assessed whether noncalcified low-
attenuation plaque burden on coronary CT angiography (CCTA) might be 
a better predictor of the future risk of myocardial infarction.
METHODS: In a post hoc analysis of a multicenter randomized controlled 
trial of CCTA in patients with stable chest pain, we investigated the 
association between the future risk of fatal or nonfatal myocardial 
infarction and low-attenuation plaque burden (% plaque to vessel 
volume), cardiovascular risk score, coronary artery calcium score or 
obstructive coronary artery stenoses.
RESULTS: In 1769 patients (56% male; 58±10 years) followed up for a 
median 4.7 (interquartile interval, 4.0–5.7) years, low-attenuation plaque 
burden correlated weakly with cardiovascular risk score (r=0.34; P<0.001), 
strongly with coronary artery calcium score (r=0.62; P<0.001), and very 
strongly with the severity of luminal coronary stenosis (area stenosis, 
r=0.83; P<0.001). Low-attenuation plaque burden (7.5% [4.8–9.2] 
versus 4.1% [0–6.8]; P<0.001), coronary artery calcium score (336 [62–
1064] versus 19 [0–217] Agatston units; P<0.001), and the presence of 
obstructive coronary artery disease (54% versus 25%; P<0.001) were all 
higher in the 41 patients who had fatal or nonfatal myocardial infarction. 
Low-attenuation plaque burden was the strongest predictor of myocardial 
infarction (adjusted hazard ratio, 1.60 (95% CI, 1.10–2.34) per doubling; 
P=0.014), irrespective of cardiovascular risk score, coronary artery calcium 
score, or coronary artery area stenosis. Patients with low-attenuation 
plaque burden greater than 4% were nearly 5 times more likely to have 
subsequent myocardial infarction (hazard ratio, 4.65;  95% CI, 2.06–10.5; 
P<0.001).
CONCLUSIONS: In patients presenting with stable chest pain, low-
attenuation plaque burden is the strongest predictor of fatal or nonfatal 
myocardial infarction. These findings challenge the current perception of 
the supremacy of current classical risk predictors for myocardial infarction, 
including stenosis severity.
REGISTRATION: URL: http://www.clinicaltrials.gov; Unique identifier: 
NCT01149590.
© 2020 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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The current clinical paradigm of coronary artery disease is based on cardiovascular risk scores and the presence of obstructive stenoses in the 
coronary vasculature.1,2 Coronary computed tomog-
raphy angiography (CCTA) has the ability to visualize 
both the coronary artery lumen and any surrounding 
atherosclerotic plaque.3,4 This allows additional assess-
ment of coronary plaque burden and plaque type, both 
of which may improve our understanding of coronary 
atherosclerosis and cardiovascular risk prediction.5,6
Coronary artery calcium scoring on noncontrast 
computed tomography (CT) using the Agatston meth-
od7 has been widely used as a surrogate marker of 
coronary plaque burden, providing powerful cardiovas-
cular risk prediction8,9 that is additive to traditional car-
diovascular risk scores.10,11 However, these macrocal-
cified plaques are generally considered a more stable 
form of atherosclerosis and, hence, relatively unlikely 
to rupture and cause myocardial infarction directly.12 
There is considerable interest in quantifying the burden 
of less stable plaque components that might more di-
rectly contribute to events.
Histological plaque characteristics that have been 
associated with plaque rupture and myocardial infarc-
tion include inflammation, microcalcification, a thin fi-
brous cap, and a large lipid-rich necrotic core.13–15 On 
CCTA, a lipid rich necrotic core can be detected as low-
attenuation noncalcified plaque.16 We have recently 
demonstrated that visually identifying such plaque may 
be of benefit in predicting the future risk of myocardial 
infarction.17 However, such qualitative assessments are 
relatively subjective, time consuming, and nonquantita-
tive. Recent developments now allow the reproducible 
and semiautomatic quantification of the burden of cal-
cified, noncalcified, and low-attenuation plaque across 
the coronary arteries on contrast CT angiography.18,19
This study aimed to investigate whether quantifica-
tion of CCTA-defined low-attenuation plaque improves 
the prediction of fatal or nonfatal myocardial infarction 
compared with cardiovascular risk scores, Agatston 
coronary artery calcium scoring, and the severity of ob-
structive coronary artery disease in stable patients with 
chest pain undergoing CCTA.
METHODS
Study Design
The data supporting the findings of this study are available 
from the corresponding author for checking the reproducibility 
of the study results. The SCOT-HEART multicenter randomized 
controlled trial (Scottish Computed Tomography of the HEART) 
assessed the use of CCTA in patients with suspected angina 
attributable to coronary artery disease (ClinicalTrials.gov. Unique 
identifier: NCT01149590).20 The study was approved by the local 
ethics committee and written informed consent was provided by 
all participants. The primary results have been published previ-
ously.21–23 Patients attending cardiology outpatient clinics were 
randomized to standard care or standard care plus CT. Of the 
4146 trial participants, 2073 were randomized to undergo CT. Of 
these, 1778 underwent CT and 1769 scans were available and 
of suitable quality for analysis in this substudy. Cardiovascular risk 
was calculated using the ASSIGN (Assessing cardiovascular risk 
using SIGN guidelines) cardiovascular risk score.24 This is a well-
validated risk score based on the Framingham risk score and has 
been calibrated to the Scottish population.
CT Imaging
Participants underwent both noncontrast electrocardiogram-
gated CT for calcium scoring and contrast enhanced electro-
cardiogram-gated CCTA.20 Imaging was performed at one 
of three sites using either 64- or 320-detector row scanners 
(Brilliance 64, Philips Medical Systems, Netherlands; Biograph 
mCT, Siemens, Germany; Aquilion ONE, Toshiba Medical 
Systems, Japan). Tube current, voltage, and volume of iodine-
based contrast were adjusted based on body mass index.
Visual Assessment of CT
Coronary artery calcium score and coronary artery ste-
nosis assessments were obtained from the SCOT-HEART 
Clinical Perspective
What Is New?
• Quantitative assessment of atherosclerotic plaque 
on coronary computed tomography angiography 
can be used to measure the burden of calcified, 
noncalcified, and low-attenuation plaque, as well 
as the total coronary plaque burden, providing 
important prognostic information.
• In this study, low-attenuation plaque was the 
strongest predictor of fatal or nonfatal myocar-
dial infarction, exceeding other established mark-
ers including cardiovascular risk scores, computed 
tomography calcium scoring, and coronary artery 
stenoses.
• Patients with a low-attenuation plaque burden 
>4% were 5 times more likely to suffer a fatal or 
nonfatal myocardial infarction.
What Are the Clinical Implications?
• The burden of low-attenuation coronary plaque 
can be measured semiautomatically on standard 
coronary computed tomography angiography 
scans, with the potential for widespread clinical 
adoption.
• This method provides incremental prediction of 
myocardial infarction to standard assessments of 
cardiovascular risk scores, computed tomography 
calcium scoring or luminal stenosis severity.
• Further studies should investigate whether this 
novel approach can used to guide clinical decision 
making and improve patient outcomes.
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database. Coronary artery calcium score was assessed using 
the Agatston scoring method, as described previously.7,20 
Coronary artery stenoses were visually assessed on a 15-seg-
ment basis by trained observers with excellent inter- and 
intraobserver variability, as described previously.25 In brief, the 
luminal area stenosis was here visually classified as normal, 
nonobstructive (<50% in left main stem or <70% in other 
segments), and obstructive (≥50% in left main stem or ≥70% 
in other segments). Obstructive coronary artery disease was 
defined as the presence of 1 or more major epicardial vessel 
with an obstructive stenosis.
Quantitative Assessment of CT
Quantitative assessment of atherosclerotic plaque sub-
types was performed using standardized semiautomatic 
software (Autoplaque, Version 2.5, Cedars-Sinai Medical 
Center) by 1 of 4 trained observers. Excellent interobserver, 
intraobserver, and interscan agreement has previously been 
established for this technique (Spearman r=0.87–0.99).18,26 
Quantitative analysis was performed for all patients who 
had 1 or more segments of nonobstructive or obstructive 
disease or a coronary artery calcium score greater than 0. 
For patients with normal coronary arteries, the plaque vol-
umes and burden were set to 0.
Coronary artery centerlines were extracted using a semi-
automated method. A circular region of interest was placed 
in the proximal aorta to define the normal reference blood 
pool attenuation. The proximal and distal aspects of coronary 
artery segments with atherosclerotic plaque were manually 
defined. Scan-specific thresholds for plaque constituents were 
generated, as described previously.27 Vessel lumen, wall, and 
plaque constituents were automatically identified, with man-
ual adjustment performed as required (Figure 1). Automatic 
quantification of area stenosis at the narrowest point of the 
segmented lumen was performed.
Plaque volumes (in mm3) were measured for the fol-
lowing plaque subtypes: total plaque, calcified plaque, 
noncalcified plaque and low-attenuation plaque (defined 
by an attenuation of <30 Hounsfield units [HU]).19 Plaque 
burden (as a percentage) was calculated for each of the 
total plaque, noncalcified plaque, low-attenuation plaque, 
and calcified plaque, by dividing the relevant plaque vol-
ume by the vessel volume of the region assessed, mul-
tiplying by 100, and summing on a per patient basis.19 
Plaque burden was used as our primary assessment for 
each plaque type.
Outcomes
The primary event for this substudy was the occurrence 
of fatal or nonfatal myocardial infarction. Information on 
cardiovascular events and mortality was obtained from 
the electronic Data Research and Innovation Service of 
the National Health Services Scotland and were confirmed 
by review of the patient’s electronic health records where 
required. Follow-up was administratively censored as of 
January 1, 2018, for patients without an event. Scottish 
health record linkage has previously been shown to have an 
excellent correlation (>95%) for accurately identifying clini-
cal events recorded and adjudicated as part of a regulated 
clinical trial.28
Statistical Analysis
Statistical analysis was performed using R, version 3.5.0 (R 
Foundation for Statistical Computing, Vienna, Austria). 
Quantitative data are presented as mean and standard devia-
tion or, if not normally distributed, as median and inter-
quartile interval (IQI). Statistical significance was assessed 
using Pearson chi-square test, Fisher exact test, Student t 
test, Kruskal–Wallis test, or Mann–Whitney U test as appro-
priate. Correlations for variables that were not normally 
Figure 1. Coronary CT angiography (CCTA) plaque analysis.
Images from a 67-year-old female who presented with atypical chest pain. She was a nonsmoker with a history of hypertension, a previous transient ischemic 
attack, and normal exercise tolerance test. Her 10-year cardiovascular risk score was 14%, coronary artery calcium score was 62 Agatston units, and coronary 
computed tomography angiography identified obstructive disease in the left anterior descending (LAD) and first diagonal. Curved planar reformations show (A) 
proximal LAD, (B) first diagonal, and (C) mid-LAD. Red overlay illustrates noncalcified plaque in the individual segment only, but all plaque in each vessel was 
analyzed for the per patient assessment. D, Shows a zoomed in view of the mid LAD plaque with blue lumen, red noncalcified plaque and orange low-attenuation 
plaque. She subsequently presented with acute myocardial infarction and underwent invasive coronary angiography (E).
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distributed were assessed using Spearman rank order correla-
tion. Correlation coefficients of <0.2 were regarded as very 
weak, 0.2 to <0.40 as weak, 0.40 to <0.60 as moderate, 0.6 
to <0.80 as strong, and 0.8 to 1 as very strong. Outcome data 
were analyzed using Cox proportional hazards regression and 
presented graphically using cumulative incidence plots using 
the Kaplan–Meier method. Hazard ratios (HR) and 95% CI 
were calculated from the Cox model. Deaths not classified 
as coronary heart disease deaths were censored for both the 
Cox regression analysis and the cumulative incidence plots. 
Univariable analysis was performed for all quantified plaque 
parameters. Multivariable models were constructed includ-
ing the individual plaque parameters and Agatston coro-
nary artery calcium score. Coronary artery calcium score and 
plaque burdens were log transformed for analysis. Receiver 
operating characteristic (ROC) curve analysis was performed 
to identify the optimum cut-off for low-attenuation plaque 
burden to identify patients at increased risk of coronary heart 
disease death or nonfatal myocardial infarction using Youden 
J statistic. A statistically significant difference was defined as 
a 2-sided P value <0.05. The imaging data that support the 
findings of this study are available from the corresponding 
author upon reasonable request.
RESULTS
Patient Population
This substudy included all 1769 patients where CCTA 
images were of suitable image quality for analysis. The 
mean age of these patients was 58±10 years, 56% were 
male, and the mean 10-year cardiovascular risk score 
was 18±11% (Table 1). The median coronary artery cal-
cium score was 21 (IQI, 0–230) Agatston units. Normal 
coronary arteries were identified in 646 patients (37%), 
nonobstructive coronary artery disease in 671 patients 
(38%) and obstructive coronary artery disease in 452 
patients (26%). The median total plaque burden for all 
patients (Table 2) was 39% (IQI, 0–49), with noncalci-
fied plaque burden 36% (IQI, 0–46), low-attenuation 
plaque burden 4.2% (IQI, 0–6.9), and calcified plaque 
burden 0.4% (IQI, 0–2.8).
Cardiovascular Risk Score and Plaque 
Type
Compared with those with a cardiovascular risk score 
≤10, patients with a cardiovascular risk score >10 had 
an increase in all subtypes of plaque burden (P<0.001 
for all) (Table 2). Similarly, patients with a cardiovascu-
lar risk score >20 had a higher low-attenuation plaque 
burden, total plaque burden, and calcified plaque than 
patients with a score ≤20. There was a weak corre-
lation between cardiovascular risk scores and total 
plaque burden (r=0.34; P<0.001) (Figure 2), and weak 
to moderate correlations with plaque burden subtypes 
including low-attenuation plaque (r=0.34; P<0.001) 
(Figure 2 and 3).
Coronary Artery Calcium Score and 
Plaque Type
A very strong correlation was observed between the 
Agatston coronary artery calcium score and the cal-
cified plaque burden quantified on CCTA (r=0.91; 
P<0.001) (Figure 2). Moderate to strong correlations 
were observed between the Agatston coronary artery 
calcium score and other plaque subtypes, including the 
total plaque burden (r=0.67; P<0.001), noncalcified 
plaque burden (r=0.58; P<0.001), and low-attenua-
tion plaque burden (r=0.62; P<0.001) (Figure 3). Low-
attenuation plaque burden demonstrated very strong 
correlations with the total plaque burden (r=0.87; 
P<0.001) and noncalcified plaque burden (r=0.88; 
P<0.001), and a moderate to strong correlation with 
the calcified plaque burden (r=0.63; P<0.001). Pa-
tients with an Agatston coronary artery calcium score 
greater than 400 had a higher total plaque burden 
Table 1. Study Population
All Participants
Number 1769
Male, n (%) 997 (56)
Age, y* 58±10
Body mass index, kg/m2* 30±6
Atrial fibrillation, n (%) 34 (2)
Previous coronary heart disease, n (%) 178 (10)
Previous cerebrovascular disease, n (%) 79 (4)
Previous peripheral vascular disease, n (%) 31 (2)
Smoking status, n (%)
  Current smoker 330 (19)
  Ex-smoker 593 (34)
  Nonsmoker 845 (48)
Hypertension, n (%) 608 (35)
Diabetes mellitus, n (%) 196 (11)
Family history, n (%) 765 (44)
Total cholesterol, mg/dL* 192±73
Anginal symptoms, n (%)
  Typical angina 654 (37)
  Atypical angina 432 (24)
  Nonanginal 683 (39)
Cardiovascular risk score* 18±11
CACS (Agatston units)† 21 [0–230]
CCTA, n (%)
  Normal 646 (37)
  Nonobstructive 671 (38)
  Obstructive 452 (26)
*Mean±SD.
†Median [interquartile interval].
CACS indicates Agatston coronary artery calcium score; and CCTA, coronary 
computed tomography angiography.
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and calcified plaque burden than patients with a score 
less than 400 (P<0.001). The low-attenuation plaque 
burden was numerically higher but this was not statis-
tically significant (Table 2).
Coronary Artery Stenosis and Plaque 
Type
Patients with visually assessed obstructive coronary ar-
tery disease had higher total plaque burden, calcified 
plaque burden, noncalcified plaque burden and low-at-
tenuation plaque burden compared with patients with 
nonobstructive coronary artery disease (Table 2). More-
over, for patients with 1-, 2-, and 3-vessel disease, there 
was a stepwise increase in the total plaque burden, low-
attenuation plaque burden and calcified plaque burden 
(Table I in the online-only Data Supplement).
Clinical Events
Over a median follow-up of 4.7 years (IQI, 4.0–5.7), the 
primary event point of fatal or nonfatal myocardial in-
farction occurred in 41 patients (2.3%). Patients who 
suffered a fatal or nonfatal myocardial infarction had 
higher total plaque, noncalcified plaque, low-attenua-
tion plaque and calcified plaque burden (Table 3; Fig-
ure  4). In univariable analysis, the total plaque, non-
calcified plaque, low-attenuation plaque and calcified 
plaque burdens were all associated with an increased 
risk of fatal or nonfatal myocardial infarction (Table 4; 
Table II in the online-only Data Supplement). In mul-
tivariable analysis, the low-attenuation plaque burden 
was the strongest predictor of the primary event (HR, 
1.60 [95% CI, 1.10–2.34] per doubling; P=0.014), add-
ing incremental value to the cardiovascular risk score 
(HR, 1.00 [95% CI, 0.98–1.03]; P=0.821), coronary 
artery calcium score (HR, 1.13 [95% CI, 1.01–1.27]; 
P=0.041), and the presence of visually observed ob-
structive coronary artery disease (HR, 1.20 [95% CI, 
0.58–2.48]; P=0.621) (Table  4; Table III in the online-
only Data Supplement).
Receiver operating characteristic curve analysis iden-
tified that the optimum threshold for low-attenuation 
plaque burden was 4%. Patients with a low-attenua-
tion plaque burden above this threshold were nearly 5 
times more likely to suffer a fatal or nonfatal myocar-
dial infarction (HR, 4.65 [95% CI, 2.06–10.5]; P<0.001) 
(Figure 5). This discriminatory ability was particularly im-
portant in patients with nonobstructive coronary artery 
disease (Table IV and Figures 1 and 2 in the online-only 
Data Supplement). Patients with nonobstructive coro-
nary artery disease and low-attenuation plaque burden 
>4% were more than 6 times more likely to suffer a 
fatal or nonfatal myocardial infarction compared with 
patients with normal coronary arteries (HR, 6.61 [95% 
CI, 1.91 to 22.82]; P=0.003), but patients with nonob-
structive disease and a low-attenuation plaque burden 
Table 2.  Quantitative Plaque Burden in Patients With Different Cardiovascular Risk Scores, Coronary Artery 
Calcification, and CCTA Findings
Plaque Burden Parameter (%)
Total Plaque 
Burden
Noncalcified 
Plaque burden
Low-Attenuation 
Plaque Burden
Calcified Plaque 
Burden
All patients* 39 [0–49] 36 [0–46] 4.2 [0–6.9] 0.4 [0–2.8]
10-year cardiovascular risk score (%)*
  ≤10 0 [0–37] 0 [0–35] 0 [0–3.9] 0 [0–0.1]
  >10–20 41 [0–51] 38 [0–48] 4.9 [0–7.4] 0.7 [0–2.8]
  >20 44 [33–51] 40 [30–46] 5.4 [2.8–7.4] 1.6 [0–5.1]
  P value† <0.001 <0.001 <0.001 <0.001
CACS (Agatston units)*
  0–99 0 [0–44] 0 [0–42] 0 [0–5.6] 0 [0–0.4]
  100–400 45 [39–51] 43 [36–48] 6.0 [4.2–8.4] 2.5 [1.6–3.9]
  >400 49 [44–55] 42 [36–47] 6.4 [4.7–8.0] 6.9 [4.5–10.7]
  P value‡ <0.001 0.46 0.44 <0.001
CCTA*
 Nonobstructive disease 44 [38–51] 42 [35–49] 5.7 [4.0–7.5] 1.1 [0.3–3.0]
  Obstructive disease 50 [44–56] 45 [39–51] 7.0 [5.4–9.0] 3.8 [1.6–7.6]
  P value <0.001 <0.001 <0.001 <0.001
*Median [interquartile interval].
†P value for patients with a cardiovascular risk score >20% versus other patients.
‡ P value for patient with CACS >400 versus CACS 100–400 Agatston units.
CACS indicates Agatston coronary artery calcium score; and CCTA, coronary computed tomography angiography.
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≤4% were not at a significantly increased risk (HR, 1.33 
[95% CI, 0.14–12.77]; P=0.806).
DISCUSSION
In this large multicenter study, we have shown that 
quantitative assessment of atherosclerotic plaque can 
identify patients who are at an increased risk of coro-
nary events. Low-attenuation plaque burden was the 
strongest predictor of outcome, with patients with a 
low-attenuation plaque burden >4% 5 times more 
likely to suffer a fatal or nonfatal myocardial infarction. 
Despite collinearity and strong correlations, this associ-
ation remained irrespective of cardiovascular risk score, 
Agatston coronary artery calcium score or the presence 
of obstructive coronary artery disease. We conclude 
that low-attenuation plaque burden is the best predic-
tor of clinical outcome, and that this underscores the 
dominant nature of plaque burden and plaque type in 
the pathogenesis of myocardial infarction.
Markers of plaque burden provide powerful predic-
tion of cardiovascular events on the basis that the more 
plaque a patient has, the more likely an individual lesion 
will rupture and cause myocardial infarction. However, 
plaque type is also important, with plaque rupture most 
commonly associated with inflamed plaques with a thin 
fibrous cap and large necrotic core.14 The latter can be 
detected on CT as low-attenuation plaque, although 
it has previously been challenging to quantify the bur-
den of low-attenuation plaque across the coronary 
vasculature. This is now possible in a rapid and robust 
fashion with semiautomatic software. In this study, we 
have demonstrated that low-attenuation plaque pro-
vides more powerful prediction of clinical events than 
cardiovascular risk score, Agatston coronary artery cal-
cium scoring, or the presence and severity of obstruc-
tive coronary artery disease. Indeed, our data would 
suggest that these other markers are associated with 
clinical events by virtue of their association with low-
attenuation plaque burden, and that it is preferable to 
measure low-attenuation plaque directly for optimum 
patient risk stratification.
This study provides further evidence of the limita-
tions of cardiovascular risk scores in the prediction of 
cardiac events. Cardiovascular risk scores are widely 
used in clinical practice to assess the requirement for 
preventative therapy,29 and play a central role in the 
management pathways for patients with suspected 
coronary artery disease, in both US and European 
guidelines.1,2 In this study, cardiovascular risk score 
demonstrated only moderate correlation with low-
attenuation plaque burden. Such scores are therefore 
limited in their ability to identify patients with the 
atherosclerotic plaque at risk of subsequent events, 
perhaps explaining their poor prognostic performance 
here and in other studies.30
Figure 2. Correlations between plaque 
burden subtypes, calcium score, coronary 
stenosis and cardiovascular risk score.
Correlations between plaque burden subtypes 
and Agatston coronary artery calcium score, 
coronary artery area stenosis and ASSIGN 
(Assessing cardiovascular risk using SIGN 
guidelines) cardiovascular risk score. P<0.001 
for all. CACS indicates Agatston coronary artery 
calcium score.
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Coronary artery calcification is widely used as a 
marker of coronary artery disease and is associated with 
an increased risk of subsequent cardiac events.9,17,31 In 
this study, we have shown that quantification of calcifi-
cation on CCTA correlates well with the Agatston cor-
onary artery calcium score performed on noncontrast 
CT, highlighting that there is limited value to additional 
noncontrast imaging when CCTA is performed. How-
ever, similar to the cardiovascular risk score, assessment 
of coronary artery calcification only provides risk by as-
sociation, quantifying stable calcified plaques rather 
than the disease that causes subsequent cardiac events. 
When the Agatston coronary artery calcium score was 
first established, CCTA had not been developed for 
routine clinical use, and the calcium score was a useful 
surrogate for the presence of coronary artery disease. 
Indeed, we have previously reported that it is a strong 
predictor of outcome, outperforming qualitative assess-
ments of adverse coronary artery plaque.17 However, 
quantitative CCTA analysis now provides assessment of 
coronary plaque burden, with the added ability of more 
accurately quantifying the plaque type most closely as-
sociated with events.
Figure 3. Correlations between low-atten-
uation plaque burden, cardiovascular risk 
score, calcium score and coronary stenosis.
Correlations between total low-attenuation 
plaque burden and 10-year cardiovascular risk 
score, Agatston coronary artery calcium score, 
and coronary artery area stenosis. CACS indi-
cates Agatston coronary artery calcium score.
Table 3.  Quantitative Assessment of Plaque in Patients With and 
Without a Primary Event of Coronary Heart Disease Death or Nonfatal 
Myocardial Infarction
No event Event P Value
Plaque burden (%)* 39 [0–49] 50 [43–54] <0.001
Noncalcified plaque burden (%)* 35 [0–45] 42 [37–49] <0.001
Low-attenuation plaque burden (%)* 4.1 [0–6.8] 7.5 [4.8–9.2] <0.001
Calcified plaque burden (%)* 0.4 [0–2.7] 3.2 [1.4–8.2] <0.001
*Median [interquartile interval].
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The identification of obstructive coronary artery 
stenosis is central to the diagnosis and manage-
ment approach of patients presenting with chest 
pain. It is an established and powerful predictor of 
an increased risk of subsequent cardiac events which 
is embedded within clinical practice. It is a central 
tenet of cardiology that this risk increases with the 
number of vessels involved.5,32 However, most coro-
nary events occur in segments that do not have 
obstructive stenoses on preceding imaging,33–35 and 
percutaneous coronary intervention on coronary ar-
tery stenoses does not prevent or reduce subsequent 
rates of myocardial infarction.36 This study provides 
support for the hypothesis that obstructive disease is 
indirectly associated with subsequent outcomes be-
cause of its correlation with plaque burden. Indeed, 
we observed a stepwise increased in plaque burden, 
including low-attenuation plaque, on moving from 
patients with nonobstructive coronary artery disease 
to those with 1-, 2- and 3-vessel obstructive coronary 
artery disease. Therefore, similar to the cardiovascu-
lar risk scores and calcium scoring, we propose that 
the predictive ability of obstructive coronary artery 
stenoses is, at least in part, attributable to its associa-
tion with the low-attenuation plaque.
Quantitative assessment of plaque can provide stan-
dardized assessment with good observer variability 
and correlation with intravascular ultrasound.27 Previ-
ous studies have identified that CCTA plaque burden 
is associated with subsequent outcomes, including 
the ICONIC (Incident Coronary Syndromes Identified 
by Computed Tomography) substudy of the CONFIRM 
(Coronary CT Angiography Evaluation for Clinical Out-
comes: An International Multicenter) registry37 and 
the PARADIGM (Progression of Atherosclerotic Plaque 
Figure 4. Plaque burden and fatal or nonfatal myocardial infarction.
Quantitative assessment of atherosclerotic plaque burden in patients with and without a primary event of fatal or nonfatal myocardial infarction (P≤0.01 for all). 
CACS indicates Agatston coronary artery calcium score, and MI, myocardial infarction.
Table 4.  Univariable and Multivariable Analysis for Plaque Subtypes 
and the Primary End Point of Fatal or Nonfatal Myocardial Infarction
Univariable Multivariable *
Hazard Ratio† P Value Hazard Ratio† P Value
Plaque burden‡ 1.46 (1.18–1.82) <0.001 1.23 (0.95–1.60) 0.119
Noncalcified 
plaque burden‡
1.43 (1.17–1.76) <0.001 1.21 (0.94–1.56) 0.140
Low-
attenuation 
plaque burden‡
1.91 (1.41–2.57) <0.001 1.60 (1.10–2.34) 0.014
Calcified 
plaque burden‡
1.75 (1.42–2.16) <0.001 1.42 (0.90–2.25) 0.133
*Multivariable analysis including the individual quantitative plaque measures, 
Agatston coronary artery calcium score, the presence of visually observed 
obstructive coronary artery disease, and cardiovascular risk score. Full model 
results are presented in Table III in the online-only Data Supplement.
†Hazard ratio (95% CI).
‡ Per doubling.
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Determined by Computed Tomographic Angiography 
Imaging) registry.38 Low-attenuation plaque in par-
ticular has been associated with an increased risk.39–41 
This is in keeping with our data and the concept that 
plaques with large necrotic cores are more prone to 
rupture than more stable calcified plaque subtypes.
This study has several limitations. It used a single 
technique to analyze plaque. Further investigation and 
external validation are required for this to become ac-
cepted and part of clinical practice and these should 
also incorporate analysis from more than one type of 
scanner or reconstruction algorithm. Although several 
parts of the analysis performed in this study were auto-
mated, the assessment of plaque type across the entire 
coronary tree takes 20 to 30 minutes.41 Future software 
incorporating further automation and machine learning 
techniques, would therefore help facilitate more wide-
spread clinical adoption. In addition, further quantified 
parameters such as pericoronary adipose tissue attenu-
ation, radiomic analyses, or positron emission tomog-
raphy features may provide additional information on 
cardiovascular risk in addition to the plaque parameters 
assessed in this study.12,42,43 Finally, in the SCOT-HEART 
trial, treatment was instigated based on CCTA find-
ings, and we cannot exclude the possibility that these 
treatment decisions may have influenced our findings. 
However, we would suggest that such interventions are 
likely to make our estimates of the association and ef-
fect sizes conservative.
In conclusion, this large multicenter study shows that 
an increased burden of low-attenuation plaque is the 
principal predictor of increased coronary events, above 
and beyond other established classic markers of cardio-
vascular risk, including coronary artery stenosis severity.
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